April 17 (Reuters) - An advisory panel to the U.S. Food andDrug Administration recommended on Wednesday that the agencyapprove an experimental treatment for smoking-related lungdamage made by GlaxoSmithKline Plc and Theravance Inc.
The drug, Breo, is an inhaled treatment for chronicobstructive pulmonary disease (COPD), a condition that includesemphysema, chronic bronchitis or both. COPD is the third-leadingcause of death in the United States, according to federal data.
Analysts were expecting a favorable review based on the FDAstaff review, which was posted to the FDA's website on Monday. (Reporting By Toni Clarke in Washington; Editing by Gerald E.McCormick)
Glaxosmithkline (GSK)
